Boston Scientific treats the 1st patient in a clinical trial of its Precision neurostimulation implant in treatment of the pain associated with chronic migraine.
Massachusetts medical device giant Boston Scientific (NYSE:BSX) announced the start of a new clinical trial to evaluate the use of neurostimulation in treatment of chronic migraines.
Boston Scientific’s OPTIMISE trial is a randomized, placebo-controlled study assessing occipital nerve stimulation as a novel approach to treating migraines by masking the pain.
Patients are given a programmable implant that stimulates the greater occipital nerve, a method that has shown promise in early studies for reducing pain associated with chronic migraine.
